Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group

Dorte Lisbet Nielsen; Karsten D Bjerre; Erik H Jakobsen; Søren Cold; Lars Eric Stenbygaard; Peter G Sørensen; Claus Kamby; Susanne Møller; Charlotte L T Jørgensen; Michael Andersson

doi:10.1200/JCO.2010.33.9507

Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group

Dorte Lisbet Nielsen, Karsten D Bjerre, Erik H Jakobsen, Søren Cold, Lars Eric Stenbygaard, Peter G Sørensen, Claus Kamby, Susanne Møller, Charlotte L T Jørgensen, Michael Andersson

Afdeling for Kræftbehandling HGH

28 Citationer (Scopus)

Abstract

The objective of this phase III study was to compare the efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with advanced breast cancer.

Originalsprog	Engelsk
Tidsskrift	Journal of Clinical Oncology
Vol/bind	29
Udgave nummer	36
Sider (fra-til)	4748-54
Antal sider	7
ISSN	0732-183X
DOI	https://doi.org/10.1200/JCO.2010.33.9507
Status	Udgivet - dec. 2011

Adgang til dokumentet

10.1200/JCO.2010.33.9507

Andre filer og links

Link to publication in Scopus

Fingeraftryk

Dyk ned i forskningsemnerne om 'Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Nielsen, D. L., Bjerre, K. D., Jakobsen, E. H., Cold, S., Stenbygaard, L. E., Sørensen, P. G., Kamby, C., Møller, S., Jørgensen, C. L. T., & Andersson, M. (2011). Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. Journal of Clinical Oncology, 29(36), 4748-54. https://doi.org/10.1200/JCO.2010.33.9507

Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. / Nielsen, Dorte Lisbet; Bjerre, Karsten D; Jakobsen, Erik H et al.
I: Journal of Clinical Oncology, Bind 29, Nr. 36, 12.2011, s. 4748-54.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Nielsen, DL, Bjerre, KD, Jakobsen, EH, Cold, S, Stenbygaard, LE, Sørensen, PG, Kamby, C, Møller, S, Jørgensen, CLT & Andersson, M 2011, 'Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group', Journal of Clinical Oncology, bind 29, nr. 36, s. 4748-54. https://doi.org/10.1200/JCO.2010.33.9507

Nielsen DL, Bjerre KD, Jakobsen EH, Cold S, Stenbygaard LE, Sørensen PG et al. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. Journal of Clinical Oncology. 2011 dec.;29(36):4748-54. doi: 10.1200/JCO.2010.33.9507

Nielsen, Dorte Lisbet ; Bjerre, Karsten D ; Jakobsen, Erik H et al. / Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. I: Journal of Clinical Oncology. 2011 ; Bind 29, Nr. 36. s. 4748-54.

@article{00fb2c2d0daf40d3886df78ca68de25f,

title = "Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group",

abstract = "The objective of this phase III study was to compare the efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with advanced breast cancer.",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Deoxycytidine, Female, Humans, Middle Aged, Neoplasm Metastasis, Proportional Hazards Models, Receptor, erbB-2, Taxoids",

author = "Nielsen, \{Dorte Lisbet\} and Bjerre, \{Karsten D\} and Jakobsen, \{Erik H\} and S{\o}ren Cold and Stenbygaard, \{Lars Eric\} and S{\o}rensen, \{Peter G\} and Claus Kamby and Susanne M{\o}ller and J{\o}rgensen, \{Charlotte L T\} and Michael Andersson",

year = "2011",

month = dec,

doi = "10.1200/JCO.2010.33.9507",

language = "English",

volume = "29",

pages = "4748--54",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "36",

}

TY - JOUR

T1 - Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group

AU - Nielsen, Dorte Lisbet

AU - Bjerre, Karsten D

AU - Jakobsen, Erik H

AU - Cold, Søren

AU - Stenbygaard, Lars Eric

AU - Sørensen, Peter G

AU - Kamby, Claus

AU - Møller, Susanne

AU - Jørgensen, Charlotte L T

AU - Andersson, Michael

PY - 2011/12

Y1 - 2011/12

N2 - The objective of this phase III study was to compare the efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with advanced breast cancer.

AB - The objective of this phase III study was to compare the efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with advanced breast cancer.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Breast Neoplasms

KW - Deoxycytidine

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Proportional Hazards Models

KW - Receptor, erbB-2

KW - Taxoids

UR - https://www.scopus.com/pages/publications/84555218405

U2 - 10.1200/JCO.2010.33.9507

DO - 10.1200/JCO.2010.33.9507

M3 - Journal article

C2 - 22084374

SN - 0732-183X

VL - 29

SP - 4748

EP - 4754

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 36

ER -